Salivary microRNAs Show Potential as a Noninvasive Biomarker for Detecting Resectable Pancreatic Cancer

Early surgery is vital in the treatment of pancreatic cancer, which is often fatal. However, there is currently no useful noninvasive biomarker to screen for pancreatic cancer. Studies have documented that many salivary molecules can be used to detect systemic diseases. We investigated whether salivary miRNAs are useful biomarkers for detecting resectable pancreatic cancer. Using an Agilent microarray, salivary miRNAs were profiled from saliva samples of 8 patients with resectable pancreatic cancer and 8 healthy controls. Candidate biomarkers identified in the profiles were subjected to validation using quantitative PCR and an independent sample set of 40 patients with pancreatic cancer, 20 with benign pancreatic tumors (BPT), and 40 healthy controls. The validated salivary miRNA biomarkers were evaluated within three discriminatory categories: pancreatic cancer versus healthy control, pancreatic cancer versus BPT, and pancreatic cancer versus noncancer (healthy control + BPT). miR-3679-5p showed significant downregulation in the pancreatic cancer group within the three categories (P = 0.008, 0.007, and 0.002, respectively), whereas miR-940 showed significant upregulation in pancreatic cancer (P = 0.006, 0.004, and 0.0001, respectively). Logistic regression models combining the two salivary miRNAs were able to distinguish resectable pancreatic cancer within the three categories, showing sensitivities of 72.5%, 62.5%, and 70.0% and specificities of 70.0%, 80.0%, and 70.0%, respectively. Salivary miR-3679-5p and miR-940 possess good discriminatory power to detect resectable pancreatic cancer, with reasonable specificity and sensitivity. This report provides a new method for the early detection of pancreatic cancer and other systemic diseases by assessing salivary miRNAs. Cancer Prev Res; 8(2); 165–73. ©2014 AACR.

[1]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  David Elashoff,et al.  Salivary Transcriptome Diagnostics for Oral Cancer Detection , 2004, Clinical Cancer Research.

[3]  C. Rosty,et al.  Early detection of pancreatic carcinoma. , 2002, Hematology/oncology clinics of North America.

[4]  J. Cheng,et al.  High resolution of microRNA signatures in human whole saliva. , 2011, Archives of oral biology.

[5]  David Elashoff,et al.  Discovery and Preclinical Validation of Salivary Transcriptomic and Proteomic Biomarkers for the Non-Invasive Detection of Breast Cancer , 2010, PloS one.

[6]  Q. Ma,et al.  CA 19-9 and pancreatic cancer. , 2013, Clinical advances in hematology & oncology : H&O.

[7]  J. K. Lee,et al.  Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.

[8]  David Elashoff,et al.  Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. , 2010, Gastroenterology.

[9]  G. Eibl,et al.  Systemic Disease-Induced Salivary Biomarker Profiles in Mouse Models of Melanoma and Non-Small Cell Lung Cancer , 2009, PloS one.

[10]  T. Homma,et al.  CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience , 1994, Pancreas.

[11]  David Elashoff,et al.  Salivary protein factors are elevated in breast cancer patients. , 2008, Molecular medicine reports.

[12]  Dongfeng Li,et al.  Salivary MicroRNAs as Promising Biomarkers for Detection of Esophageal Cancer , 2013, PloS one.

[13]  D. Wong,et al.  Salivary diagnostics: moving to the next level. , 2012, Dentistry today.

[14]  M. Tomita,et al.  Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles , 2009, Metabolomics.

[15]  G. Illei,et al.  MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome. , 2011, Arthritis and rheumatism.

[16]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[17]  D. Wong,et al.  Saliva: an emerging biofluid for early detection of diseases. , 2009, American journal of dentistry.

[18]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[19]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[20]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[21]  M. Duffy,et al.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  U. Ballehaninna,et al.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review , 2011, Indian journal of surgical oncology.

[23]  David Elashoff,et al.  Development of transcriptomic biomarker signature in human saliva to detect lung cancer , 2012, Cellular and Molecular Life Sciences.

[24]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[25]  John T McDevitt,et al.  Current developments in salivary diagnostics. , 2010, Biomarkers in medicine.

[26]  A. Vissink,et al.  Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. , 2007, Arthritis and rheumatism.

[27]  David S Ostreicher Saving lives: toothbrushes trump seat belts. , 2012, Dentistry today.

[28]  N. Park,et al.  Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection , 2009, Clinical Cancer Research.

[29]  R. Molina,et al.  CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer , 2012, Tumor Biology.

[30]  D. Chia,et al.  Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer , 2011, Gut.

[31]  Jae Hoon Kim,et al.  Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma , 2011, Journal of Molecular Medicine.

[32]  David Elashoff,et al.  Discovery and Prevalidation of Salivary Extracellular microRNA Biomarkers Panel for the Noninvasive Detection of Benign and Malignant Parotid Gland Tumors , 2013, Clinical Cancer Research.

[33]  Zijun Xie,et al.  Saliva supernatant miR-21: a novel potential biomarker for esophageal cancer detection. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[34]  G. Illei,et al.  Exosomes from human saliva as a source of microRNA biomarkers. , 2010, Oral diseases.

[35]  David Elashoff,et al.  Salivary Proteomics for Oral Cancer Biomarker Discovery , 2008, Clinical Cancer Research.

[36]  Fuqiang Wen,et al.  Diagnostic value of microRNA for pancreatic cancer: a meta-analysis , 2012, Archives of medical science : AMS.

[37]  C. Croce Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. , 2012, Cancer journal.